FNCHライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:14):

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States...

Stats
本日の出来高	13 318.00
平均出来高	45 680.00
時価総額	3.63M
EPS	$0 ( 2024-03-28 )
次の収益日	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0500
ATR14	$0.0330 (1.46%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Smisek Jeffery A	Sell	1 600	Common Stock
2024-03-28	Smisek Jeffery A	Sell	6 642	Common Stock
2023-11-22	Smisek Jeffery A	Sell	1 470	Common Stock
2023-06-09	Blischak Matthew P.	Buy	962 899	Stock Option (right to buy)
2023-06-08	Blischak Matthew P.	Buy	962 899	Stock Option (right to buy)

INSIDER POWER
97.83
Last 84 transactions
Buy: 22 938 760 \| Sell: 28 923 806

ボリューム相関

長: 0.12 (neutral)

短: -0.52 (weak negative)

Signal:(46.008) Neutral

Finch Therapeutics Group, 相関

10 最も正の相関
ACET	0.917
VNDA	0.917
AFMD	0.914
COMT	0.91
GROM	0.903
STRC	0.889
EQRX	0.889
AYLA	0.883
ADSE	0.882
TRVN	0.874

10 最も負の相関
IDLB	-0.867
ISDX	-0.855
EVOP	-0.839
QADA	-0.815
LMRK	-0.812
ISEM	-0.811

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Finch Therapeutics Group, 相関 - 通貨/商品

0.63
( weak )

0.64
( weak )

0.00
( neutral )

0.54
( weak )

0.17
( neutral )

-0.62
( weak negative )

Finch Therapeutics Group, 財務諸表

Annual	2023
収益:	$107 000
総利益:	$-1.41M (-1 320.56 %)
EPS:	$-46.59

FY	2023
収益:	$107 000
総利益:	$-1.41M (-1 320.56 %)
EPS:	$-46.59

FY	2022
収益:	$861 000
総利益:	$-4.65M (-539.61 %)
EPS:	$-71.52

FY	2021
収益:	$18.53M
総利益:	$18.53M (100.00 %)
EPS:	$-1.676

Financial Reports:

No articles found.

Finch Therapeutics Group,

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.